Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.1210 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:00 PM ET.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%.The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. On average, analysts expect Cardiff Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cardiff Oncology Stock Down 2.6%

Shares of Cardiff Oncology stock opened at $2.24 on Thursday. Cardiff Oncology has a 12 month low of $1.90 and a 12 month high of $5.64. The business has a fifty day simple moving average of $2.16 and a 200 day simple moving average of $2.82. The stock has a market cap of $149.03 million, a PE ratio of -2.57 and a beta of 1.62.

Analyst Ratings Changes

A number of research firms have issued reports on CRDF. HC Wainwright cut their price target on Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, October 8th. Finally, LADENBURG THALM/SH SH assumed coverage on Cardiff Oncology in a report on Tuesday, July 8th. They issued a “buy” rating and a $19.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.63.

Hedge Funds Weigh In On Cardiff Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new position in shares of Cardiff Oncology in the second quarter valued at approximately $43,000. BNP Paribas Financial Markets grew its position in Cardiff Oncology by 335.1% during the second quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company’s stock worth $49,000 after buying an additional 11,889 shares in the last quarter. Bank of America Corp DE grew its position in Cardiff Oncology by 189.3% during the second quarter. Bank of America Corp DE now owns 93,393 shares of the company’s stock worth $294,000 after buying an additional 61,110 shares in the last quarter. Glenview Trust co grew its position in Cardiff Oncology by 79.9% during the second quarter. Glenview Trust co now owns 43,128 shares of the company’s stock worth $136,000 after buying an additional 19,150 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Cardiff Oncology by 23.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock worth $69,000 after buying an additional 4,232 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.